Moderna Inc said it will apply for US and European emergency authorization of its COVID-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns.The drug company also reported a 100% success rate in preventing severe Covid-19 cases.
The filing sets Moderna's product up to be the second vaccine likely to receive US emergency use authorization this year after Pfizer-BioNTech's vaccine candidate, which is 95% effective.The trial results come at a time when the coronavirus pandemic has infected over 63 million people and killed more than 1.4 million across the world.Of these, US hospitals have been stretched to the limit as the nation has seen more than 160,000.